NRG-BR009

Open to Accrual

Return to Protocol Table

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)

Principal Investigator

Eleftherios Mamounas, MD MPH

Status

Open to Accrual

Date Opened To Accrual

August 31 2023

Disease Site

Breast [BR]

Breast

Phase

III

Developmental Therapeutics

Primary Objective

To determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

Patient Population

Premenopausal patients with early-stage, HER2-negative breast cancer that is sensitive to hormones, and have an Oncotype DX Recurrence Score(R) equal to or less than 25.

Target Accrual

3960

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Other

NRG-BR009, the OFSET Study Overview by Terry Mamounas, MD & Shannon Puhalla, MD(July 2023)

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.